Cargando…
Therapeutic inhibition of Mcl-1 blocks cell survival in estrogen receptor-positive breast cancers
Cancers often overexpress anti-apoptotic Bcl-2 proteins for cell death evasion, a recognized hallmark of cancer progression. While estrogen receptor (ER)-α+ breast cancers express high levels of three anti-apoptotic Bcl-2 family members (Bcl-2, Bcl-xL, and Mcl-1), pharmacological inhibition of Bcl-2...
Autores principales: | Williams, Michelle M., Elion, David L., Rahman, Bushra, Hicks, Donna J., Sanchez, Violeta, Cook, Rebecca S. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739218/ https://www.ncbi.nlm.nih.gov/pubmed/31595181 http://dx.doi.org/10.18632/oncotarget.27070 |
Ejemplares similares
-
ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactation
por: Williams, Michelle M., et al.
Publicado: (2017) -
Intrinsic apoptotic pathway activation increases response to anti-estrogens in luminal breast cancers
por: Williams, Michelle M., et al.
Publicado: (2018) -
Bcl-2 family proteins in breast development and cancer: could Mcl-1 targeting overcome therapeutic resistance?
por: Williams, Michelle M., et al.
Publicado: (2015) -
Harnessing RIG-I and intrinsic immunity in the tumor microenvironment for therapeutic cancer treatment
por: Elion, David L., et al.
Publicado: (2018) -
CDK9 inhibitors selectively target estrogen receptor-positive breast cancer cells through combined inhibition of MYB and MCL-1 expression
por: Mitra, Partha, et al.
Publicado: (2016)